PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.40
D/E ratio exceeding 1.5x Medical - Pharmaceuticals median of 0.04. Howard Marks would check for debt covenant compliance and refinancing risks.
-1.88
Net cash position versus Medical - Pharmaceuticals median net debt of 1.06. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
68.25
Coverage of 68.25 versus zero Medical - Pharmaceuticals median interest expense. Walter Schloss would verify if our leverage provides advantages.
0.91
Current ratio below 50% of Medical - Pharmaceuticals median of 2.00. Michael Burry would check for immediate refinancing needs.
0.65%
Intangibles less than half the Medical - Pharmaceuticals median of 5.69%. Warren Buffett would verify if this conservative approach misses valuable brand-building opportunities.